France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

03/02/2016 - 2 minutes

Open Innovation is now everywhere, even Pharma. So, just today in France, the opening of the Pierre Fabre Fund for Innovation for biotech startups has been announced. 

pierre_fabre_pharma_innovation_biotechMost Big Pharma have their own program. Boehringer-Ingelheim for example is partnering with BioMedX to run a new program with researchers from Heidelberg. Now the 3rd largest Pharma company in France, Pierre Fabre, has also made a move into the field.

Pierre Fabre will accompany its biotech and research laboratories specialized in oncology and dermatology, primarily in France and Europe. This program aims to speed up the development process of new molecules from preclinical to clinical phases, and will last between 12 and 24 months. The support provided will consist of sharing expertise or funding, primarily targeted at young European biotechs.

Pierre Fabre’s official goal is to help French and European innovative Biotech companies to develop their innovation faster. But the ultimate vision is even larger, as for every Pharma, to get in on the development of the drug and be able to in-license it more easily (instead of paying the bubbly partnership fees).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member